# Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3

> **NCT03363854** · PHASE3 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 380 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Tralokinumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03363854
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-22
- **Primary completion:** 2019-03-08
- **Final completion:** 2019-09-26
- **Target enrollment:** 380 (ACTUAL)
- **Last updated:** 2025-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03363854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03363854, "Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03363854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*